Drug intelligence / Profile preview

VLP001

Development stage: Preclinical
Lead developer: Allergy Therapeutics
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous, Percutaneous

Overview

VLP001 is a preclinical virus-like particle (VLP) vaccine candidate developed by Saiba Biotech for the treatment of peanut allergy. The vaccine utilizes Saiba's proprietary VLP platform to present peanut allergens in a highly repetitive, multivalent format, which is intended to induce a protective immune response while minimizing allergic reactivity. VLP001 has been evaluated in ex-vivo biomarker studies using blood samples from peanut-allergic patients to assess its ability to interact with IgE and T-cells. It serves as a precursor and proof-of-concept for Saiba's lead clinical program, VLP-Peanut.

Targets

Arachis hypogaea allergen 2-specific B-cell receptorFCGR2B (Fc gamma receptor IIB)TCR-TT(p30) (T-cell receptor recognizing the Tetanus Toxoid p30 epitope)Ara h 2

Beyond the preview

Go deeper on VLP001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VLP001.

Explore the full profile